Free Trial
NASDAQ:ENTX

Entera Bio (ENTX) Stock Price, News & Analysis

Entera Bio logo
$2.35 +0.28 (+13.53%)
As of 04/24/2025 04:00 PM Eastern

About Entera Bio Stock (NASDAQ:ENTX)

Key Stats

Today's Range
$1.98
$2.39
50-Day Range
$1.60
$2.35
52-Week Range
$1.41
$2.79
Volume
169,213 shs
Average Volume
81,563 shs
Market Capitalization
$106.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
Consensus Rating
Buy

Company Overview

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Entera Bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
45th Percentile Overall Score

ENTX MarketRank™: 

Entera Bio scored higher than 45% of companies evaluated by MarketBeat, and ranked 491st out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Entera Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Entera Bio has only been the subject of 1 research reports in the past 90 days.

  • Read more about Entera Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Entera Bio are expected to decrease in the coming year, from ($0.28) to ($0.55) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Entera Bio is -9.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Entera Bio is -9.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Entera Bio has a P/B Ratio of 6.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Entera Bio's valuation and earnings.
  • Percentage of Shares Shorted

    0.23% of the float of Entera Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Entera Bio has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Entera Bio has recently decreased by 13.12%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Entera Bio does not currently pay a dividend.

  • Dividend Growth

    Entera Bio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.23% of the float of Entera Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Entera Bio has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Entera Bio has recently decreased by 13.12%, indicating that investor sentiment is improving significantly.
    • Insider Buying vs. Insider Selling

      In the past three months, Entera Bio insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      10.90% of the stock of Entera Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

    • Percentage Held by Institutions

      Only 14.11% of the stock of Entera Bio is held by institutions.

    • Read more about Entera Bio's insider trading history.
    Receive ENTX Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Entera Bio and its competitors with MarketBeat's FREE daily newsletter.

    ENTX Stock News Headlines

    Entera Bio Reports Transformative Year in 2024
    Now I look stupid. Real stupid...
    I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
    Entera Bio Ltd.
    Opko Health, Entera Bio enter into collaboration agreement
    See More Headlines

    ENTX Stock Analysis - Frequently Asked Questions

    Entera Bio's stock was trading at $2.12 at the beginning of the year. Since then, ENTX shares have increased by 10.8% and is now trading at $2.35.
    View the best growth stocks for 2025 here
    .

    Entera Bio Ltd. (NASDAQ:ENTX) posted its earnings results on Friday, March, 28th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.02. The company had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.04 million.

    Entera Bio (ENTX) raised $11 million in an IPO on Thursday, June 28th 2018. The company issued 1,400,000 shares at a price of $8.00 per share. Maxim Group served as the underwriter for the IPO and Joseph Gunnar was co-manager.

    Shares of ENTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Entera Bio investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY) and GE Aerospace (GE).

    Company Calendar

    Last Earnings
    3/28/2025
    Today
    4/24/2025
    Next Earnings (Estimated)
    5/09/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    Biological products, except diagnostic
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:ENTX
    Fax
    N/A
    Employees
    20
    Year Founded
    N/A

    Price Target and Rating

    Average Stock Price Target
    $10.00
    High Stock Price Target
    $10.00
    Low Stock Price Target
    $10.00
    Potential Upside/Downside
    +325.5%
    Consensus Rating
    Buy
    Rating Score (0-4)
    3.00
    Research Coverage
    1 Analysts

    Profitability

    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    $-8,890,000.00
    Pretax Margin
    -9,270.71%

    Debt

    Sales & Book Value

    Annual Sales
    $181,000.00
    Price / Cash Flow
    N/A
    Book Value
    $0.36 per share
    Price / Book
    6.53

    Miscellaneous

    Free Float
    31,884,000
    Market Cap
    $106.74 million
    Optionable
    Optionable
    Beta
    1.47
    7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

    Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

    Get This Free Report

    This page (NASDAQ:ENTX) was last updated on 4/25/2025 by MarketBeat.com Staff
    From Our Partners